Literature DB >> 31392062

Direct oral anticoagulants in gastrointestinal malignancies: is the convenience worth the risk?

Namisha Thapa1, Joseph Shatzel2, Thomas G Deloughery2, Sven R Olson2.   

Abstract

Entities:  

Year:  2019        PMID： 31392062      PMCID： PMC6657330          DOI： 10.21037/jgo.2019.02.07

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


× No keyword cloud information.
  7 in total

1.  Gastrointestinal Bleeding With Oral Anticoagulation: Understanding the Scope of the Problem.

Authors:  Muthiah Vaduganathan; Deepak L Bhatt
Journal:  Clin Gastroenterol Hepatol       Date:  2017-01-12       Impact factor: 11.382

2.  Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.

Authors:  Noémie Kraaijpoel; Marcello Di Nisio; Frits I Mulder; Nick van Es; Jan Beyer-Westendorf; Marc Carrier; David Garcia; Michael Grosso; Ajay K Kakkar; Michele F Mercuri; Saskia Middeldorp; Cristhiam Rojas Hernandez; Amparo Santamaria; Lee Schwocho; Annelise Segers; Peter Verhamme; Tzu-Fei Wang; Jeffrey I Weitz; George Zhang; Jeffrey I Zwicker; Harry R Büller; Gary E Raskob
Journal:  Thromb Haemost       Date:  2018-07-30       Impact factor: 5.249

3.  Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.

Authors:  Ang Li; David A Garcia; Gary H Lyman; Marc Carrier
Journal:  Thromb Res       Date:  2018-03-02       Impact factor: 3.944

4.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

Authors:  Agnes Y Y Lee; Mark N Levine; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Frederick R Rickles; Jim A Julian; Susan Haley; Michael J Kovacs; Michael Gent
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

5.  Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.

Authors:  Gary E Raskob; Nick van Es; Peter Verhamme; Marc Carrier; Marcello Di Nisio; David Garcia; Michael A Grosso; Ajay K Kakkar; Michael J Kovacs; Michele F Mercuri; Guy Meyer; Annelise Segers; Minggao Shi; Tzu-Fei Wang; Erik Yeo; George Zhang; Jeffrey I Zwicker; Jeffrey I Weitz; Harry R Büller
Journal:  N Engl J Med       Date:  2017-12-12       Impact factor: 91.245

6.  Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

Authors:  Annie M Young; Andrea Marshall; Jenny Thirlwall; Oliver Chapman; Anand Lokare; Catherine Hill; Danielle Hale; Janet A Dunn; Gary H Lyman; Charles Hutchinson; Peter MacCallum; Ajay Kakkar; F D Richard Hobbs; Stavros Petrou; Jeremy Dale; Christopher J Poole; Anthony Maraveyas; Mark Levine
Journal:  J Clin Oncol       Date:  2018-05-10       Impact factor: 44.544

7.  Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.

Authors:  A A Khorana; S Noble; A Y Y Lee; G Soff; G Meyer; C O'Connell; M Carrier
Journal:  J Thromb Haemost       Date:  2018-07-19       Impact factor: 5.824
  7 in total
  1 in total

Review 1.  Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants.

Authors:  Robert Benamouzig; Maxime Guenoun; David Deutsch; Laurent Fauchier
Journal:  Cardiovasc Drugs Ther       Date:  2021-06-18       Impact factor: 3.947
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.